Article

Diurnal variability of C-reactive protein in obstructive sleep apnea

Department of Psychiatry, University of California, San Diego, La Jolla, 92093-0804, USA.
Sleep And Breathing (Impact Factor: 2.87). 06/2009; 13(4):415-20. DOI: 10.1007/s11325-009-0268-0
Source: PubMed

ABSTRACT The objective of this study is to examine the diurnal variability of C-reactive protein (CRP) in obstructive sleep apnea (OSA).
Participants included 44 women and men with untreated OSA (mean apnea/hypopnea index = 37.5, SD +/- 28) and 23 healthy adults with no OSA. Sleep was monitored with polysomnography in the University of California San Diego General Clinical Research Center. Over a 24-h period, blood was collected every 2 h, and CRP levels were determined.
Adjusting for age, gender, and body mass index, a significant group by time interaction showed that patients with OSA had higher CRP levels during the daytime (8:00 a.m.-8:00 p.m.) versus the nighttime (10:00 p.m. until 6:00 p.m.; p < 0.001). Non-apneics showed no significant change in CRP levels during the 24 h.
The findings indicate that sleep apnea patients have disproportionately elevated CRP levels in the day versus the nighttime, possibly as a result of carryover effects of nighttime arousal into the daytime.

Full-text

Available from: Sonia Ancoli-Israel, May 04, 2015
1 Follower
 · 
89 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: In the light of relationships reported between hypoxemia (tissue hypoxia) and cancer, Abrams et al. concluded in 2008 that sleep apnea-hypopnea syndrome (SAHS) and its main consequence, intermittent hypoxia, could be related with increased susceptibility to cancer or poorer prognosis of a pre-existing tumor. This pathophysiological association was confirmed in animal studies. Two large independent historical cohort studies subsequently found that the degree of nocturnal hypoxia in patients with SAHS was associated with higher cancer incidence and mortality. This finding has been confirmed in almost all subsequent studies, although the retrospective nature of some requires that they be considered as hypothesis-generating only. The relationship between sleep apnea and cancer, and the pathophysiological mechanisms governing it, could be clarified in the near future in a currently on-going study in a large group of melanoma patients.
    Archivos de Bronconeumología 04/2015; DOI:10.1016/j.arbres.2015.02.002 · 1.82 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: This study investigated morning levels of pentraxin3 (PTX3) as a sensitive biomarker for acute inflammation in patients with obstructive sleep apnea (OSA). A total of 61 consecutive patients with OSA were divided into two groups: non-to-mild (n=20) and moderate-to-severe (n=41) OSA based on their apnea-hypopnea index (AHI) score. Those patients with moderate-to-severe OSA were further divided into continuous positive airway pressure (CPAP)-treated (n =21) and non-CPAP-treated (n=20) groups. Morning and evening serum PTX3 and high-sensitivity (hs)-C reactive protein (CRP) levels were measured before and after 3 months of CPAP therapy. The baseline hs-CRP and PTX3 levels were higher in patients with moderate-to-severe OSA than in those with non-to-mild OSA. Moreover, the serum PTX3, but not the hs-CRP, levels were significantly higher after than before sleep in the moderate-to-severe OSA group (morning PTX3; 1.96±0.52, evening PTX3; 1.71±0.44ng/mL). OSA severity as judged using the AHI was significantly correlated with serum PTX3, but not hs-CRP, levels. The highest level of correlation was found between the AHI and morning PTX3 levels (r=0.563, p<0.001). CPAP therapy reduced evening and morning serum hs-CRP and PTX3 levels in patients with moderate-to-severe OSA; however, the reduction in PTX3 levels in the morning was greater than that in the evening (morning: -29.8±16.7% vs. evening:-12.6±26.8%; p=0.029). Improvement in the AHI score following CPAP therapy was strongly correlated with reduced morning PTX3 levels(r=0.727, p<0.001). Based on these results, morning PTX3 levels reflect OSA-related acute inflammation, and are a useful marker for improvement in OSA following CPAP therapy.
    Journal of Applied Physiology 09/2014; 117(10). DOI:10.1152/japplphysiol.00237.2014 · 3.43 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Despite its high prevalence and frequent association with multiple comorbidities, including hypertension, heart disease, and stroke, obstructive sleep apnea (OSA) still lacks appropriate tools for cardiovascular risk assessment and stratification. Circulating biomarkers represent a safe, convenient, and inexpensive possibility, and several studies have been performed to define an ideal marker in this context. Additionally, biomarkers can provide insight into the pathological mechanisms of the disease and suggest new therapeutic approaches. In the present review, the authors critically analyze the biomarkers of cardiovascular risk currently available and other potential markers, including brain natriuretic peptide, C-reactive protein, tumor necrosis factor alpha (TNF-alpha), interleukin 6 (IL-6), cysteine, homocysteine, free fatty acids, 8-isoprostane, gamma-glutamyl transferase, glycated hemoglobin, adipokines, and adhesion molecules. The results clearly demonstrate that the relationship between specific biomarkers and OSA is often influenced by age, gender or ethnicity, which has hindered the identification of a unique marker for the evaluation of all patients with OSA. Moreover, given the frequency of comorbidities in OSA, which, by themselves, increase the cardiovascular risk, all confounding factors must be considered in the evaluation of these biomarkers.